m7Gpp

m7Gpp Suppliers list
Company Name: Zhejiang Hengkang Pharmaceutical Co., Ltd.
Tel: +86-576-83372028 +86-18868723926
Email: bd1@hengkangpharm.cn
Products Intro: Product Name:M7Gpp
CAS:531553-69-2
Purity:99% Package:1ml;0.00;USD|10ml;0.00;USD|400ml;0.00;USD
Company Name: Jinan Carbotang Biotech Co.,Ltd.
Tel: +8615866703830
Email: figo.gao@foxmail.com
Products Intro: Product Name:m7Gpp
CAS:531553-69-2
Purity:98% Package:5KG;1KG
Company Name: Henan Aochuang Chemical Co.,Ltd.
Tel: +86-0371-63689365 +8618638391208
Email: sales@aochuangchem.com
Products Intro: Product Name:m7Gpp
CAS:531553-69-2
Purity:98% Package:1kg,10kg,25kg
Company Name: JinOu Biomedical (Nanjing) Co., Ltd.  
Tel: 13000000000
Email: jinoupharma@163.com
Products Intro: CAS:531553-69-2
Purity:99% HPLC Package:100G;1KG;100KG
Company Name: Jiangsu Synthgene Biotechnology Co.,Ltd.  
Tel: 18136497538
Email: znf@syngenebio.com
Products Intro: Product Name:Im-m7GDP
CAS:531553-69-2
Purity:98% Package:1g;10g;100g Remarks:IM7G2001-1;IM7G2001-10;IM7G2001-100;

m7Gpp manufacturers

  • M7Gpp
  • M7Gpp pictures
  • $0.00 / 1ml
  • 2023-04-04
  • CAS:531553-69-2
  • Min. Order: 1ml
  • Purity: 99%
  • Supply Ability: 1000L per month
m7Gpp Basic information
Product Name:m7Gpp
Synonyms:m7Gpp
CAS:531553-69-2
MF:C14H19N7O10P2
MW:507.29
EINECS:
Product Categories:
Mol File:531553-69-2.mol
m7Gpp Structure
m7Gpp Chemical Properties
Safety Information
MSDS Information
m7Gpp Usage And Synthesis
Usesm7Gpp is an important intermediate for the synthesis of mRNA cap analogs.
Clinical claims and researchmRNA Cap analogs has the highest cost in all raw materails of mRNA vaccine. Like modified GAG, mofied GGG, etc. the synthetic steps are more than 18 operations. The total prorcess field is less than 15%. How to cut the cost of mRNA Cap analogs is the significant job for the mRNA commerial production.
Current market and forecastRecent developments in mRNA cap analogs highlight the importance of mRNA as a powerful tool for studying RNA metabolism and uncover the potential of targeted mRNAs for cancer treatment, gene therapy, antiviral therapy and improved targeting of nuclease-targeted drugs.
Chemically modified mRNA cap analogs consist of the unique cap structure m7G [5'] ppp [5'] N (where N = G, A, C or U) and are present in many eukaryotic and viral 5' end RNAs and several non-coding RNAs. the presence of sugar substitutions on the m7G portion of the cap analog has a significant impact on the orientation, translation efficiency, binding affinity and nature of nuclear stability.
The synthesis of various cap analogs with 7-methylguanosine (m7G) sugar substitution modifications is a rather complex organic synthesis, usually with more than 18 reaction steps, using reagents and raw materials not readily available, such as 3'-propynyl, 2', 3'-isopropylidene, 2', 3'-diacetyl and 2' -amino, triphosphate bridging, e.g. iminodiphosphate and methylenebis(phosphonate); triphosphate non-bridging, e.g., BH3, Se and S; and nucleobase substitutions, e.g., 6-thioguanosine and triazole.
m7Gpp Preparation Products And Raw materials
Tag:m7Gpp(531553-69-2) Related Product Information
BIS(2-CYANOETHYL)-N,N-DIISOPROPYL PHOSPHORAMIDITE 2-Cyanoethyl N,N,N',N'-tetraisopropylphosphorodiamidite 2’-O-Methyl-rA(N-Bz)phosphoramidite 2'-O-Methyladenosine Guanosine, 5'-O-[bis(4-methoxyphenyl)phenylmethyl]-N-(2-methyl-1-oxopropyl)-, 2',3'-diacetate Guanosine-9-17N, N-(2-methyl-1-oxopropyl)-, 2',3'-diacetate